Roche partners with Zealand Pharma to advance petrelintide in obesity treatment
Roche has entered into an exclusive collaboration and licensing agreement with Zealand Pharma to develop and commercialise petrelintide obesity treatment, a promising amylin analog therapy ... Read More
Zealand Pharma announces promising results from dapiglutide trial for obesity treatment
Zealand Pharma A/S (Nasdaq: ZEAL), a pioneer in peptide-based drug development, has shared topline results from its DREAM trial, evaluating the efficacy of low doses ... Read More
Survodutide shows promising results in Phase 2 study for weight loss in obese people
Boehringer Ingelheim and Zealand Pharma have announced further data showcasing the superior efficacy of survodutide (BI 456906) compared to placebo in individuals with overweight or ... Read More